Abstract: Nowadays, as the demand for accurate object detection (OD) applications is increasing, several attempts have been made to introduce convolutional neural network (CNN)-based super-resolution ...
Abstract: Current adversarial attacks pose a serious threat to the robustness of visual-language models (VLMs), including vision-language pre-trained models (VLPMs) and multimodal large language ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...
Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
If only they were robotic! Instead, chatbots have developed a distinctive — and grating — voice. Credit...Illustration by Giacomo Gambineri Supported by By Sam Kriss In the quiet hum of our digital ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback